Floatz logo

Ato

Myeloid Malignancy

Ascentage Pharma Group Inc.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Myeloid Malignancy cohort.

Asset / SponsorPhaseRating
Venetoclax
First Affiliated Hospital of Zhejiang University
Phase 3BB
ETOPOSIDE
University of California, San Francisco
Phase 3BB
Vesanoid
Ascentage Pharma Group Inc.
Phase 3BB
Arsenic Trioxide
Ruijin Hospital
Phase 3BB
Decitabine
Benjamin Tomlinson
Phase 2BB

View all 22 →

Same molecule, other indications

Ato is also rated in:

CLL/SLLDormant
B
Indicative ·
60 / 100
View asset →
Acute Promyelocytic Leukemia (APL)Dormant
B
Indicative ·
57 / 100
View asset →
Mantle Cell Lymphoma (MCL)Dormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →